However, its future trajectory is far from linear as many uncertainties remain, e.g., acceptance of obesity as a chronic disease, budget impact faced by payers and health systems willingness and ability to pay, the readout of further cardiovascular outcomes trials after the high profile results of 2023s SELECT trial for Wegovy, or new entrants challenging first generation therapies with alternative mechanisms of action (MoA) to address shortcomings such as gastrointestinal tolerability, current drugs being injectables, or the durability and quality of weight loss which distinguishes between fat and lean body mass
After 68 weeks, half of the participants using semaglutide lost 15% of their body weight, and nearly a third lost 20%
L-carnitine in Dog Food Let's talk about L-carnitine
Role of the bloodbrain barrier in the nutrition of the central nervous system
Leung N, Bridoux F, Batuman V, Chaidos A, Cockwell P, DAgati VD, et al